Clinical trial · Interventional
Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
Dose Finding Phase 1 Study of the Treatment of Recurrent/Relapsed Glioblastoma Multiforme With MPC-6827 in Combination With Carboplatin
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open-label, dose finding, multiple-dose study in subjects with recurring/relapsing glioblastoma multiforme. Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts. Study endpoints will include determination of the maximum tolerated dose, dose limiting toxicities, and evaluation of evidence of anti-tumor activity of MPC-6827 when given with carboplatin.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma Multiforme | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MPC-6827 + Carboplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Maximum tolerated dose
- timeFrame
- After each cohort is enrolled and all subjects have completed 1 cycle
Secondary outcomes (2)
- measure
- Pharmacokinetics
- timeFrame
- Cycle 1 only
- measure
- Antitumor activity
- timeFrame
- Screening, end of each cycle, end of study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven WHO Grade IV glioblastoma multiforme at time of diagnosis or relapse * Prior treatment with radiotherapy and temozolomide * Evidence of measurable recurrent or residual primary tumor by contrast-enhanced MRI * Be a minimum of 4 weeks since prior surgical resection, major surgical procedure, radiation therapy or cytotoxic chemotherapy (6 weeks since prior BCNU or CCNU) * Have a Performance Scale of Karnofsky \> 60%, ECOG \< 2 or WHO \< 2 * If steroids are needed, be on a stable or decreasing dose of steroids for at least 1 week Exclusion Criteria: * Hypersensitivity to Cremophor EL * Have evidence of current/active intratumor hemorrhage by MRI * Have greater than second relapse * Have had prior treatment with platinum-based chemotherapy * Have cardiovascular disease * Have cerebrovascular disease * Have uncontrolled hypertension * Have a cardiac ejection fraction \< 50% * Have Troponin-I elevated above the normal range
References
Publications (0)
Data not yet available